Browsing by Author Nott, Louise M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2015Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumabGebski, Val; Price, Timothy; Sjoquist, Katrin; et al, Various; Field, Kathryn; Gibbs, Peter; McKendrick, J; Nott, Louise M; Roohullah, Aflah; Shapiro, Jeremy; Tran, Ben; Wong, Hui-Li; Yip, Desmond; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreGastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab, World Journal of Gastroenterology, vol.21, 17, 2015,pp 5352-5358
2016ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursGebski, Val; Khasraw, Mustafa; Pavlakis, Nick; Thavaneswaran, Subotheni; Wilson, Kate; Chantrill, Lorraine A; Day, Fiona; Desai, Jayesh; Elez, Elena; et al, Various; Jefford, Michael; Nott, Louise M; Segelov, Eva; Underhill, Craig; Waring, Paul; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours, BMC Cancer, vol.16, 1, 2016,pp 1-8
2015Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLCClarke, Stephen; Abdi, E; Button, Peter; Clingan, Philip R.; Do, Hongdo; Dobrovic, Alexander N; Gregory, Daniel; Michael, Michael; Nott, Louise M; Solomon, Benjamin; White, Shane C; Zimet, A; Northern Clinical School: Kolling InstituteMulticenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC, Asia-Pacific Journal of Clinical Oncology, vol.11, 1, 2015,pp 4-14
2013Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 TrialSimes, Robert John; Zalcberg, John; Charpentier, Danielle; Couture, Felix; et al, Various; Jonker, Derek J.; Karapetis, Christos (Chris); Moore, Malcolm; Nott, Louise M; Price, Timothy; Shapiro, Jeremy; Siddiqui, Jehan; Siu, Lillian L; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePhase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial, Journal of Clinical Oncology, vol.31, 19, 2013,pp 2477-2484
2016Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyGebski, Val; Khasraw, Mustafa; Pavlakis, Nick; Robledo, Kristy; Simes, Robert John; Thavaneswaran, Subotheni; Wilson, Kate; Chantrill, Lorraine A; Desai, Jayesh; Elez, Elena; et al, Various; Karapetis, Christos (Chris); Lunke, Sebastian; Nott, Louise M; Segelov, Eva; Underhill, Craig; Waring, Paul; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; School of Molecular Bioscience (SMB)Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study, Journal of Clinical Oncology, vol.34, 19, 2016,pp 2258-2264